RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Jefferies 2016 Healthcare Conference

36 slides from RespireRx Pharmaceuticals's conference presentation, Jun 8, 2016

  1. Slide 1: Medicines for Respiratory Diseases

    Slide 1: Medicines for Respiratory Diseases

    RespireRx Pharmaceuticals Inc OTC QB: RSPI James S. Manuso, Ph.D., President & CEO JEFFERIES 2016 HEALTHCARE CONFERENCE JUNE 7. 2016, NEW YORK, NY Medicines for Respiratory Diseases

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements Resp pireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," "intends," "exp

  3. Slide 3: Breath

    Slide 3: Breath

    Breath ax "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." vases Abbot George Burke

  4. Slide 4: Innovative Medicines for Respiratory Diseases

    Slide 4: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases GQ RespireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 or Phase 2-ready development programs o Three pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent

  5. Slide 5: Company Focus

    Slide 5: Company Focus

    eo} fe) 1e) fe) ie} Company Focus KW Sleep Apneas = Dronabinol for Obstructive Sleep Apnea (OSA) = Ampakines for Central Sleep Apnea (CSA) Drug-induced Respiratory Depression (RD) - Ampakines = Acute use — surgical anesthesia/sedation = Semi-acute use — post-surgical pain management with opioids = C

  6. Slide 6: Respiratory Diseases Product Pipeline

    Slide 6: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline GQ RespireRx Pharmaceuticals Inc Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea Central Sleep Apnea ee CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation CX717 with Opioids for Reduced Repertory Depression CX

  7. Slide 7: Sleep Apnea

    Slide 7: Sleep Apnea

    Sleep Apnea A) RespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed o The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sleep apneas =

  8. Slide 8: Obstructive Sleep Apnea (OSA)

    Slide 8: Obstructive Sleep Apnea (OSA)

    Obstructive Sleep Apnea (OSA) A) RespireRx Pharmaceuticals Inc o Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep = Induced by relaxation of muscles during sleep = Soft tissue in back of throat collapses and obstructs upper airway o Significant morbidity due to stro

  9. Slide 9: CPAP Efficacy is Severely Limited by Patient Compliance

    Slide 9: CPAP Efficacy is Severely Limited by Patient Compliance

    CPAP Efficacy is Severely Limited by Patient Compliance RespireRx Pharmaceuticals Inc ON Standard of Care Works as an air splint to keep upper airway open during sleep 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine Over 50% of patients stop using CPAP in the first

  10. Slide 10: Dronabinol: Breakthrough Treatment for OSA

    Slide 10: Dronabinol: Breakthrough Treatment for OSA

    Dronabinol: Breakthrough Treatment for OSA A) RespireRx o Mechanism of Action = Dronabinol is (delta 9) THC, a cannabinoid agonist o Background = Schedule III drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients and nausea and vomitin

  11. Slide 11: Completed Phase 2A Trial of Dronabinol in OSA

    Slide 11: Completed Phase 2A Trial of Dronabinol in OSA

    Completed Phase 2A Trial of Dronabinol in OSA Gd Resp pireRx Pharmaceuticals Inc o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days = 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight poly

  12. Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects

    Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects

    Dronabinol Proven to Reduce Apnea in OSA Subjects RespireRx Pharmaceuticals Inc 40% -20% -30% oO o < 30% } Qa < 20% S P=0.17 10% | 2 Dronabinol ao 0% = Placebo e “10% 5 P<0.01 = oo a nod o ir -40% 12

  13. Slide 13: Apnea Suppression as a Function of Dose and Time

    Slide 13: Apnea Suppression as a Function of Dose and Time

    Apnea Suppression as a Function of Dose and Time G&)Resp pireRx Pharmaceuticals Inc mist Half AAHI versus Baseline % 8 -12 a 2nd Half Lal n=17 n= 13 n=8 The plasma half-life of dronabinol is 2 — 4 hours. 13

  14. Slide 14: Dronabinol Phase 2B Clinical Trial in OSA

    Slide 14: Dronabinol Phase 2B Clinical Trial in OSA

    Dronabinol Phase 2B Clinical Trial in OSA Gd RespireRx o NIH-funded; conducted at 4 major centers o Dr. David Carley, U of Illinois, Principal Investigator © Potentially pivotal for an NDA submission o Doses: Placebo, 2.5 mg, 10 mg qd o All 120 subjects dosed (40/group, 6 weeks dosing) o Data analys

  15. Slide 15: Protecting Dronabinol in the Market

    Slide 15: Protecting Dronabinol in the Market

    Protecting Dronabinol in the Market Gd RespireRx Pharmaceuticals Inc o Issued Method-of-Use patent for dronabinol in OSA licensed from U Illinois = Expires in 2025 o Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use

  16. Slide 16: The Dronabinol Opportunity

    Slide 16: The Dronabinol Opportunity

    The Dronabinol Opportunity Gd RespireRx Pharmaceuticals Inc Impact on Patient Commercial Opportunity First medicine available for OSA Changes the nature of OSA treatment Ease of Use/Better Patient Compliance Broadly expands prescriber base from sleep specialists to include primary care physicians an

  17. Slide 17: Central Sleep Apnea

    Slide 17: Central Sleep Apnea

    Central Sleep Apnea Gd RespireRx o Caused by a lack of drive from the brain to breathe during sleep o Manifestations of CSA = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic o No medicine or device is approved for the CSA indication 17

  18. Slide 18: Severity of CSA is Correlated with Increased Mortality in Heart Failure Patients

    Slide 18: Severity of CSA is Correlated with Increased Mortality in Heart Failure Patients

    Severity of CSA is Correlated with Increased Mortality in R ireR Heart Failure Patients ceopee Reducing Central Sleep Apnea May Reduce Mortality in Heart Failure Patients ‘68 AHI less than § per hour ‘ooo AHI equal or greater than 5 per hour a 9) 2 70) xa Be Ee kK.) 2 10) 0 0 0 DD © 8 & 7 & 9 KO 1 B

  19. Slide 19: AMPAKINES - A Novel Class of Medicines

    Slide 19: AMPAKINES - A Novel Class of Medicines

    AMPAKINES - A Novel Class of Medicines A RespireRx Pharmaceuticals Inc AMPA Receptors Mediate Synaptic Transmission in the Brain AMPAKINE o Glutamate is the major excitatory neurotransmitter in as the CNS o Fast excitatory transmission is mediated by AMPA-type glutamate receptors o Ampakines are pos

  20. Slide 20: AMPAKINES - Novel Treatments for Respiratory Depression

    Slide 20: AMPAKINES - Novel Treatments for Respiratory Depression

    Brainstem Carotid artery Spinalcord Intercostal Initial research conducted by Dr. J. Greer, U. Alberta Ren etal, Anesthesiology. 110:1364-1370, 2009 AMPAKINES -— Novel Treatments for Respiratory Depression RN ° RespireRx PreBéotzinger PreBotzinger Complex Complex Neurons in this brainstem region con

  21. Slide 21: CX1739: A Third Generation, Oral Ampakine

    Slide 21: CX1739: A Third Generation, Oral Ampakine

    CX1739: A Third Generation, Oral Ampakine in Phase 2 GG’ RespireRx Pharmaceuticals Inc o Targeted Indications = Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression = Combination formulation with an opioid for treatment of chronic pain o Stage of Development =

  22. Slide 22: CX1739: Completed Phase 2A in Sleep Apnea

    Slide 22: CX1739: Completed Phase 2A in Sleep Apnea

    CX1739: Completed Phase 2A in Sleep Apnea A) RespireRx Pharmaceuticals Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a single dose o

  23. Slide 23: Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas

    Slide 23: Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas

    Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas Be RespireRx earres Inc Obstructive Apneas Mixed Apneas Central Apnea 38 Apnea Index (Events/hr) ean Sass Apnea Index (Events/hr) ona Nh ok oo Apnea Index (Events/hr) oN hk @ @ 23

  24. Slide 24: Drug-induced Respiratory Depression

    Slide 24: Drug-induced Respiratory Depression

    Drug-induced Respiratory Depression Go RespireRx Pharmaceuticals Inc RD is the most frequent lethal side effect of opioid use o Acute and Semi-Acute Use of opioids = ~25M patients/year at risk for Respiratory Depression (hospitalized, peri- and post-surgical opioid patients) o Chronic Opioid Use = U

  25. Slide 25: Ampakines Prevent Opioid-induced Respiratory Depression

    Slide 25: Ampakines Prevent Opioid-induced Respiratory Depression

    Ampakines Prevent Opioid-induced Respiratory Depression GR RespireRx Pharmaceuticals Inc o Two Clinical studies in normal, healthy volunteers with CX717, a second-generation Ampakine o Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil o Respiratory and

  26. Slide 26: CX717 Prevents Opioid-induced Respiratory Depression in Humans

    Slide 26: CX717 Prevents Opioid-induced Respiratory Depression in Humans

    CX717 Prevents Opioid-induced Respiratory Depression in Humans GQ RespireRx Pharmaceuticals Inc = o NS C—Placebo Gg CX717 a = S *P<0.01 NS - Not Significant Breaths/min o b re expressed as the basal respiratory rate. and 16 per group. CX717 dose is 1500mg. Baseline +Alfentanil +Naloxone Alfentanil r

  27. Slide 27: CX717 Does Not Interfere With the Analgesic Properties of Opioids

    Slide 27: CX717 Does Not Interfere With the Analgesic Properties of Opioids

    CX717 Does Not Interfere With the Analgesic Properties of Opioids AS RespireRx diesel dat ce Inc Analgesia 2.0 [Placebo p15 mamgacx717 2 2 no NS § 1.0 — 7) £ Ci a 05: Delivery of a electrical stimulation to finger Alfentanil reduced the pain sensitivity Baseline +Alfentanil +Naloxone (produced analg

  28. Slide 28: CX1739: Phase 2A in Opioid-Induced Respiratory Depression

    Slide 28: CX1739: Phase 2A in Opioid-Induced Respiratory Depression

    CX1739: Phase 2A in Opioid-Induced Respiratory Depression RespireRx Pharmaceuticals Inc Protocol Antagonism of Opioid-Induced Respiratory Depression by CX1739 with Preservation of Opioid Analgesia Design Randomized, Blinded, Placebo-controlled, Cross-Over with Dose Escalation Dosing Each subject wil

  29. Slide 29: Key Objectives for 2016

    Slide 29: Key Objectives for 2016

    Key Objectives for 2016 ing Fi i RespireRx (Pending Financing) WN diesel dat ce Inc Compound Indication Status Estimated Estimated Start Date Completion Dronabinol Obstructive Sleep Apnea Phase 2B Underway 3Q2016 CX1739 Opioid-induced RD Phase 2A 1Q2016 2Q2016 Central Sleep Apnea Phase 2A 3Q2016 2Q2

  30. Slide 30: Respiratory Diseases Product Pipeline

    Slide 30: Respiratory Diseases Product Pipeline

    Respiratory Diseases Product Pipeline GQ RespireRx Pharmaceuticals Inc Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea Central Sleep Apnea ee CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation CX717 with Opioids for Reduced Repertory Depression CX

  31. Slide 31: NIH-Supported Programs in Drug Abuse

    Slide 31: NIH-Supported Programs in Drug Abuse

    NIH-Supported Programs in Drug Abuse A) RespireRx o Non-Core Programs in Drug Abuse and Addiction Cocaine and Amphetamines Research and development program with NIDA NIDA contracts with specialist labs and pays for animal studies Company provides compounds and retains all rights 31

  32. Slide 32: Capital Structure & Market Metrics

    Slide 32: Capital Structure & Market Metrics

    Capital Structure (th & Market Metrics sands of shares) Total as of May 31, 2016 Common Stock 648,768 Common Stock Equivalents of Convertible Notes 9,153 Common Stock Equivalents of all Options and 556,251 Warrants Granted Total 1,214,172 March 8, 2016 Closing price per share of Common Stock $0.021

  33. Slide 33: Management and Directors

    Slide 33: Management and Directors

    Management and Directors Go RespireRx Pharmaceuticals Inc James Manuso President, CEO & Vice Chairman Arnold Lippa CSO & Chairman Jeff Margolis VP, Secretary/Treasurer, Director Robert Weingarten CFO, Director Richard Purcell Senior VP, R& D Katie MacFarlane Director CCO Agile Therapeutics James Sap

  34. Slide 34: Innovative Medicines for Respiratory Diseases

    Slide 34: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases A) ° ° ° fe} Two proprietary, small molecule platforms Three Phase 2 or Phase 2-ready development programs Three pre-clinical programs Focus on blockbuster markets with unmet clinical needs More than 120 + patents and patent applications Multiple opportu

  35. Slide 35: Strategic Considerations, Post-Phase II Results

    Slide 35: Strategic Considerations, Post-Phase II Results

    Strategic Considerations, Post-Phase Il Results GQ RespireRx Pharmaceuticals Inc o Prepare RSPI for an up-listing to NASDAQ o Proxy issued for a vote on a 325:1 reverse split o Engage advisor to assist with capital raising o Directly manage all trials of medicines in development o Partner/License/Se

  36. Slide 36: OTC QB: RSPI

    Slide 36: OTC QB: RSPI

    RespireRx Pharmaceuticals Inc OTC QB: RSPI James S. Manuso, Ph.D., President & CEO JEFFERIES 2016 HEALTHCARE CONFERENCE JUNE 7. 2016, NEW YORK, NY Medicines for Respiratory Diseases

Source: SEC EDGAR · 8-K filed Jun 8, 2016

More decks from RespireRx Pharmaceuticals Inc